Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Share News (MXCT)

Share Price Information for MaxCyte (MXCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 370.00
Bid: 360.00
Ask: 380.00
Change: 0.00 (0.00%)
Spread: 20.00 (5.556%)
Open: 370.00
High: 370.00
Low: 370.00
Prev. Close: 370.00
MXCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MaxCyte launches new generation of cellular engineering instruments

Mon, 08th Apr 2019 08:34

(Sharecast News) - MaxCyte on Monday launched its ExPERT technology platform, a family of instruments that are the next generation of its complex cellular engineering technology.The medicines and life sciences company said the newly introduced products introduce updated software, a touch-screen user interface and other features that deliver a significant improvement to the user experience and will enable customers to standardize on a single, unifying technology from early research through to clinical and commercial use.Brad Calvin, executive vice president of global commercial operations for MaxCyte, said: "The ExPERT instrument family is the result of extensive customer research into feature design, functionality and performance that are considered critical to enabling the next generation of cellular therapies. Creating cellular editing platforms standardized on a single, scalable, high performance technology can assist the industry in accelerating timelines, reducing costs and achieving milestones critical to the translation of this promising new generation of cellular therapies."The AIM traded company said the new products build on a foundation of its solid technology and its past instrument platforms, which are used by all of the top ten biopharmaceutical companies by revenue.Doug Doerfler, president and chief executive of MaxCyte, said: "We are proud to announce the launch of our next-generation ExPERT brand of instruments. We are committed to continually investing in our platform and delivering the essential tools, product features and technology performance that are critical to the advancement of promising new cellular therapeutics, which provide hope to many patients with previously incurable or life-threatening diseases."MaxCyte's shares were down 0.27% at 187.00p at 1143 BST.
More News
10 May 2022 11:18

MaxCyte reports good first quarter revenue growth

(Sharecast News) - Cell engineering technology company MaxCyte reported total first quarter revenue of $11.6m (£9.42m) in an update on Tuesday - an increase of 78% year-on-year.

Read more
13 Apr 2022 18:47

TRADING UPDATES: BlueRock output rises; Watkin Jones profit to fall

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
13 Apr 2022 10:45

MaxCyte CFO resigns, first quarter revenues rise

(Sharecast News) - Cell engineering company MaxCyte announced on Wednesday that Amanda Murphy has resigned from her position as chief financial officer as of 15 April, to "pursue other interests".

Read more
23 Mar 2022 17:22

MaxCyte widens net loss in 2021 while annual revenue increases

(Alliance News) - MaxCyte Inc on Wednesday posted a widened net loss of USD19.1 million in 2021, increased from a loss of USD11.8 million the year before.

Read more
23 Mar 2022 12:06

MaxCyte reports record Q4 and full-year revenue

(Sharecast News) - Cell engineering company MaxCyte reported record quarterly revenue of $10.2m (£7.73m) for the final three months of 2021 on Wednesday, up 19% year-on-year.

Read more
15 Mar 2022 15:52

UK earnings, trading statements calendar - next 7 days

Wednesday 16 March  
4imprint Group PLCFull Year Results
Advanced Medical Solutions Group PLCFull Year Results
Centamin PLCFull Year Results
Centaur Media PLCFull Year Results
CLS Holdings PLCFull Year Results
Computacenter PLCFull Year Results
Eagle Eye Solutions Group PLCHalf Year Results
Fevertree Drinks PLCFull Year Results
Gelion PLCHalf Year Results
Gym Group PLCFull Year Results
LSL Property Services PLCFull Year Results
PensionBee Group PLCFull Year Results
Pharos Energy PLCFull Year Results
Restaurant Group PLCFull Year Results
Restore PLCFull Year Results
RPS Group PLCFull Year Results
Science Group PLCFull Year Results
Thursday 17 March  
Ceres Power Holdings PLCFull Year Results
Cineworld Group PLCFull Year Results
Deliveroo PLCFull Year Results
Emis Group PLCFull Year Results
Empresaria Group PLCFull Year Results
FDM Group PLCFull Year Results
Gem Diamonds LtdFull Year Results
Harbour Energy PLCFull Year Results
Helios Towers PLCFull Year Results
Marshalls PLCFull Year Results
Mpac Group PLCFull Year Results
Ocado Group PLCQ1 Results
PensionBee Group PLCFull Year Results
Trainline PLCTrading Statement
TransGlobe Energy CorpFull Year Results
Tribal Group PLCFull Year Results
Wickes Group PLCFull Year Results
Friday 18 March  
ContourGlobal PLCFull Year Results
Essentra PLCFull Year Results
Eurocell PLCFull Year Results
Investec PLCTrading Statement
J D Wetherspoon PLCHalf Year Results
S4 Capital PLCFull Year Results
Monday 21 March 
Photo-Me International PLCFull Year Results
Spectral MD Holdings LtdFull Year Results
Sthree PLCTrading Statement
Tuesday 22 March 
Alliance Pharma PLCFull Year Results
BioPharma Credit PLCFull Year Results
Circassia Group PLCFull Year Results
Diaceutics PLCFull Year Results
Diurnal Group PLCFull Year Results
IQGeo Group PLCFull Year Results
Longboat Energy PLCFull Year Results
Luceco PLCFull Year Results
MaxCyte IncFull Year Results
MP Evans Group PLCFull Year Results
Oxford Nanopore Technologies PLCFull Year Results
Pebble Group PLCFull Year Results
Real Estate Investors PLCFull Year Results
Sabre Insurance Group PLCFull Year Results
ScS Group PLCHalf Year Results
Softcat PLCHalf Year Results
Staffline Group PLCFull Year Results
Trustpilot Group PLCFull Year Results
YouGov PLCHalf Year Results
Zotefoams PLCFull Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
10 Mar 2022 15:57

IN BRIEF: MaxCyte hires chief scientist from Stemson Therapeutics

MaxCyte Inc - Maryland-based platform for cell-based research - Hires Cenk Sumen as chief scientific officer. Sumen joins from San Diego, California-based hair-loss treatment firm Stemson Therapeutics Corp, where he was chief technology officer.

Read more
10 Mar 2022 11:17

MaxCyte taps Cenk Sumen as its chief scientific officer

(Sharecast News) - Cell engineering company MaxCyte announced the appointment of Cenk Sumen as its chief scientific officer on Thursday.

Read more
21 Feb 2022 10:01

MaxCyte to consolidate its restricted and unrestricted shares

(Sharecast News) - Cell engineering technology company MaxCyte announced the consolidation of the two lines of its common stock into a single unrestricted line of common stock on Monday.

Read more
1 Feb 2022 12:51

MaxCyte signs platform licence with biotech firm Intima

(Sharecast News) - Cell engineering platform technology company MaxCyte announced the signing of a strategic platform licence (SPL) with Intima Bioscience on Tuesday.

Read more
1 Feb 2022 12:00

MaxCyte signs strategic platform pact with Intima Bioscience

MaxCyte signs strategic platform pact with Intima Bioscience

Read more
24 Jan 2022 14:53

MaxCyte expects improved full-year revenue on organic growth

MaxCyte expects improved full-year revenue on organic growth

Read more
24 Jan 2022 09:35

MaxCyte ends year with strong trading

(Sharecast News) - Cell engineering company MaxCyte said on Monday that it expected total revenue for its fourth quarter to be at least $10m, up from $8.5m year-on-year, reflecting growth of at least 17% in total revenue and at least 37% in core business revenue.

Read more
8 Dec 2021 15:12

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
23 Nov 2021 16:21

DIRECTOR DEALINGS: New MaxCyte chair buys USD220,000 in shares

DIRECTOR DEALINGS: New MaxCyte chair buys USD220,000 in shares

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.